Avecho Biotechnology Limited Total Liabilities
Avecho Biotechnology Limited total liabilities. Based on the latest financial reports, Avecho Biotechnology Limited (OEZ) has total liabilities worth €5.55 Million EUR (≈ $6.48 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Avecho Biotechnology Limited (OEZ) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Avecho Biotechnology Limited (2013–2025)
Total liabilities of Avecho Biotechnology Limited from 2013 to 2025. This chart illustrates how Avecho Biotechnology Limited's total liabilities have evolved over time, based on quarterly financial data.
Avecho Biotechnology Limited Competitors by Total Liabilities
The table below lists competitors of Avecho Biotechnology Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seoyon Topmetal Co. Ltd
KQ:019770
|
Korea | ₩82.46 Billion |
|
Lotus KFM Bhd
KLSE:8303
|
Malaysia | RM23.52 Million |
|
Valbiotis SAS
PA:ALVAL
|
France | €7.43 Million |
|
Country Group Development Public Company Limited
BK:CGD
|
Thailand | ฿12.05 Billion |
|
Teaminvest Private Group Ltd
AU:TIP
|
Australia | AU$46.12 Million |
|
Higher Way Electronic Co Ltd
TWO:3268
|
Taiwan | NT$548.21 Million |
|
Terranet AB
ST:TERRNT-B
|
Sweden | Skr17.01 Million |
|
Galil Capital Re Spain SOCIMI SA
MC:YGCS
|
Spain | €19.06 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Avecho Biotechnology Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OEZ asset base.
Liquidity & Leverage Metrics
Avecho Biotechnology Limited Total Liabilities Ratios Explained
Avecho Biotechnology Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avecho Biotechnology Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avecho Biotechnology Limited (2013–2025)
The table below shows the annual total liabilities of Avecho Biotechnology Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.55 Million ≈ $6.48 Million |
+221.15% |
| 2024-12-31 | €1.73 Million ≈ $2.02 Million |
+83.43% |
| 2023-12-31 | €941.54K ≈ $1.10 Million |
+2.27% |
| 2022-12-31 | €920.66K ≈ $1.08 Million |
+29.79% |
| 2021-12-31 | €709.36K ≈ $829.32K |
+1.31% |
| 2020-12-31 | €700.17K ≈ $818.57K |
+25.90% |
| 2019-12-31 | €556.12K ≈ $650.17K |
-38.35% |
| 2018-12-31 | €902.04K ≈ $1.05 Million |
-50.87% |
| 2017-12-31 | €1.84 Million ≈ $2.15 Million |
+7.57% |
| 2016-12-31 | €1.71 Million ≈ $2.00 Million |
-6.00% |
| 2015-12-31 | €1.82 Million ≈ $2.12 Million |
-3.04% |
| 2014-12-31 | €1.87 Million ≈ $2.19 Million |
-14.36% |
| 2013-12-31 | €2.19 Million ≈ $2.56 Million |
-- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more